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Abstract  
The aim of this study was to investigate whether Ultra High Risk for psychosis 
(UHR) patients who present with hallucinations alone at identification as UHR are at 
lower risk of transition to psychosis than UHR patients who present with symptoms 
other than hallucinations or hallucinations plus other symptoms.  
Our primary dataset was a retrospective “case-control” study of UHR patients (N = 
118). The second, independent dataset was a long-term longitudinal follow up study 
of UHR patients (N = 416). We performed a survival analysis using Log-rank test and 
Cox regression to investigate the relationship between symptom variables and 
transition to a psychotic disorder.  
Hallucinations alone at baseline were not significantly associated with a reduced risk 
of transition to psychosis. In the case control study the presence of hallucinations 
when found in the absence of any thought disorder and visual hallucinations in the 
absence of substance misuse was associated with a reduced risk of transition to 
psychosis. In the longitudinal follow-up dataset perceptual disturbance found in the 
absence of a disorder of affect or emotion was associated with an increased risk of 
transition to psychosis. 
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1. Introduction:  
Hallucinations are sensory experiences that take place in the absence of corresponding 
external stimulation of the relevant sensory organ, in the awake state and with 
sufficient sense of reality that the individual attributes the event to being outside of 
their control (David, 2004). Hallucinations have traditionally been defined by the 
sensory modality in which they are perceived i.e. auditory, visual, gustatory, 
olfactory, somatic or tactile (Aleman and Laroi, 2008). Aleman and Laroi (2008) 
suggest that the hypotheses proposed to explain the underlying mechanism of 
hallucinations can be loosely divided into three categories  (1) hallucinations as a 
disturbance in cognitive-perceptual processes (Slade and Bentall, 1988), (2) 
hallucinations as a disturbance of metacognitive processes (Frith., 1991; Bentall., 
1990; Morrison et al., 1995) and (3) hallucinations as a disturbance of brain 
biochemistry and/ or structure (David et al., 1996; Woodruff et al., 1997; Allen et al., 
2012). While evidence exists to support many of these hypotheses, the field is yet to 
reach scientific consensus (Aleman and Laroi, 2008; Dirk Blom and Sommer, 2012).  
 
Hallucinations are a primary symptom of psychotic disorders such as schizophrenia in 
both ICD-10 and DSM-5 (World Health Organisation, 1992; American Psychiatric 
Association, 2013). 70% of patients with schizophrenia experience hallucinations, 
most commonly in the auditory modality, followed by visual hallucinations (Mueser 
et al., 1990). Hallucinations are reported in current psychiatry textbooks as key 
psychotic symptoms (Kraepelin, 1899; Jaspers, 1963; Saddock et al., 1989; Gelder et 
al., 2009). Hallucinations also appear in screening tools to detect psychotic disorders 
(Bebbington and Nayani, 1995; Konings et al., 2006).  
 
The ‘Ultra High Risk’ group (UHR), also referred to as the ‘At Risk Mental State’  
(ARMS) or “clinical high risk” (CHR) group, are a group of help seeking adolescents 
or young adults identified using reliable measurement tools and clinical criteria as 
being at very high risk of developing a psychotic illness in the near future (Yung et 
al., 2003; Miller et al., 2003). This clinically defined population was found, in initial 
studies, to have a rate of “transition” to a frank psychotic disorder of around 40% in 
the first 12 months after presentation (Yung et al., 2003; Philips et al., 2000). 
However, more recently a reduction in the transition rates has been reported in the 
literature, with authors reporting transition rates as low as 12% in 12 months 
(Morrison et al., 2012). A meta-analysis by Fusar-Poli et al. (2012) found consistent 
transition rates of 22% after 1 year, 29% after 2 years, and 36% after 3 years. These 
rates are 200- 300 times higher than would be expected in a general population 
sample. The PACE 400 dataset is the first long-term follow-up of a UHR cohort, and 
this has estimated that the overall rate of transition was 34.9% over a 10-year period 
(95% CI, 28.7%- 40.6%). The highest risk of transition was in the first 2 years of 
entry into the service (Nelson et al., 2013). Factors which have been associated with 
an increased risk of transition to psychosis in UHR samples include long duration of 
symptoms before treatment (Yung et al., 2003), basic and negative symptoms (Mason 
et al., 2004; Simon et al., 2006; Haroun et al., 2006; Yung et al., 2005), schizotypal 
disorder (Ruhrmann et al., 2010) sleep disturbances (Ruhrmann et al., 2010) and 
substance abuse (Cannon et al., 2008). Three factors of particular interest are 
subthreshold positive symptoms, (Yung et al., 2003; Mason et al., 2004; Ruhrmann et 
al., 2010; Yung et al., 2005) poor functioning, (Yung et al., 2003; Mason et al., 2004; 
Ruhrmann et al., 2010; Yung et al., 2006) and having genetic risk with functional 
decline. These three factors were found to be significant predictors in the large North 
American Prodrome Longitudinal Study (Cannon et al., 2008) and replicated in an 
independent sample (Thompson et al., 2011). Hallucinations are included in the UHR 
(ARMS/ CHR) criteria in either sub-threshold or infrequent forms as indicating high 
and imminent risk for psychosis (Yung et al., 2003).  
 
However, more recently general population studies have shown that psychotic 
symptoms and subclinical psychotic symptoms [or “psychotic like experiences” 
(PLEs)], are common in the general population (van Os, 2001). These PLE’s include 
hallucinations, delusions, thought disorder and negative symptoms. Most general 
population studies of PLEs have tended to focus on PLEs in general, without 
distinguishing between different types of PLE. However, hallucinations do appear to 
be the most prevalent PLE in general population samples (Horwood et al., 2008; 
Kelleher et al., 2012). Epidemiological studies estimate the prevalence of 
hallucinations to be between 5 and 15% in the general population (Tien, 1991; Johns 
et al., 2004). In adolescent and young adult (university) samples these estimates are 
higher with rates of between 6% and 37% reported in the literature (Dhossche et al., 
2002; Altman et al., 1997; Barrett and Etheridge, 1992). However, Johns et al., (2002) 
found that only 25% of adults reporting hallucinations met diagnostic criteria for a 
psychotic disorder. Hallucinations in adolescent populations often appear to be 
common but transitory phenomena that do not persist into adulthood (De Loore et al., 
2011).  
Numerous studies have also found that there is a non-clinical population (i.e. people 
who have never been clinically referred or have never received a psychiatric or 
neurological diagnosis) who hear voices, which they experience as benign and are not 
associated with psychological distress, functional decline or psychiatric illness 
(Romme et al., 1989; Daalman et al., 2011). These voice hearers do not seek help 
from clinical services. 
 
Hallucinations are also common in many non-psychotic psychiatric disorders and in a 
number of organic disorders. These include mood disorders where they are considered 
a marker of disorder severity (Choong et al., 2007) and borderline personality 
disorder where they are mostly auditory, distressing and tend to have a critical quality 
(Slotema et al., 2012).  
As such, hallucinations, which were once considered a classic psychotic symptom, 
now appear to be common in general population samples, not necessarily associated 
with distress or help seeking and frequently occur in non-psychotic illnesses. It is in 
this context that we felt it timely to re-examine the clinical significance in the UHR 
population of hallucinations if they and they alone are the reason for assessing 
someone as being at UHR. Only one, relatively small, study has reported that 
presence of auditory hallucinations at entry to the clinic was predictive of transition to 
psychosis (Mason et al., 2004), but this finding has not been replicated in larger 
cohorts (Ruhrmann et al., 2010; Woods et al., 2009; Nelson et al., 2013).  
 
This exploration is particularly pertinent as it has been proposed that in a given 
individual, PLEs, like hallucinations might either be: (i) an expression of an 
underlying neurological / psychological vulnerability to a psychotic disorder; (ii) an 
‘incidental’ attenuated psychotic symptom which is not necessarily associated with 
risk of psychosis but is associated with a non-psychotic illness that will remit once 
treated; or (iii) present in non-clinical normal individuals, and not associated with 
distress or disability or increased vulnerability to psychotic disorder (Yung et al., 
2009). A possible analogy, which encapsulates (i) and (ii) is to consider a 
hallucination as being like a fever. Both a hallucination and a fever are common non- 
specific symptoms that exist on a continuum with normal, are associated with some 
distress and indicate some underlying pathology. However, this underlying illness 
may be relatively benign and short-lived or something more serious and enduring.  
 
Much attention has been focused on the identification of clinical signs, symptoms or 
factors, which alone or in combination could enrich the identification of those at 
highest risk within the UHR population. However, little has been reported on the 
identification of clinical factors that alone or in combination may indicate a reduced 
risk of transition within the UHR population. In other areas of medical practice it is 
common for the presence of one symptom to be considered more or less significant 
when found in the absence of other symptoms or signs. An example would be a cough 
found in the absence of crepitations being considered less clinically concerning than 
when found with crepitations. In the UHR field, little consideration has been given to 
the clinical relevance of the presence of one particular symptom while in the absence 
of other specific symptoms, signs or clinical factors. This is important because 
‘relevant negatives’ may offer additional insight into the clinical trajectory of UHR 
patients (Yung et al., 2012).   
 
Historically the presence of visual hallucinations in the absence of other psychotic 
symptoms raised a query about organicity/ substance use (Teeple et al., 2009). 
However, possible disparities in transition rates associated with different forms of 
perceptual disturbance, in the UHR population, is an under researched area.  
 
 
1.2 Aims of this study: 
The primary aim of this study was to investigate if the presence of hallucinations 
alone at baseline in UHR individuals is associated with a reduced risk of transition to 
psychosis compared to those who present with symptoms other than hallucinations. 
The secondary aims were twofold (a) to examine if hallucinations with/ without 
specific other symptoms e.g. hallucinations with or in the absence of thought disorder, 
were more or less likely to transition to psychosis (b) certain forms of hallucinations 
e.g. visual, tactile, olfactory are associated with an even lower level of risk of 
transition.  
It is our primary hypothesis that those young people who are assessed as UHR on the 
basis of hallucinations alone are less likely to transition to psychosis than those young 
people presenting with other symptoms.  
 
2. Methods:  
We used data from two separate datasets collected at the Personal Assistance and 
Clinical Evaluation (PACE) clinic in Melbourne. Our primary dataset was a case 
control study which was developed to investigate whether specific clinical data 
characterised UHR patients who did and did not go on to develop a psychotic disorder 
(N=118). Our secondary dataset was the first long-term longitudinal follow-up of 
UHR individuals who had consented to research since 1993 (The PACE 400 study) 
(Nelson et al., 2013). We repeated some of the analyses in this dataset in an attempt to 
replicate and further validate our findings. There was some overlap of study 
participants. For the purposes of this paper these overlap participants (N=20) were 
excluded from the analyses of the PACE 400 data so as to ensure that the samples 
were independent. Ethical approval was received from the University of Melbourne to 
conduct both studies.  
 
2.1 Design 
2.1.1 Case control study 
This was a retrospective “case-control” study of patients meeting the UHR criteria 
treated at PACE, a specialised UHR clinic (Yung et al., 2007). A consecutive series of 
patients who later developed a psychotic disorder (‘cases’) between 2003 and 2008 
were identified and compared to a randomly selected sample from the clinic who had 
not developed a psychotic disorder within a defined time frame (‘controls’). For more 
detailed information on the case control study design see Figure 1.  
 
2.1.2 PACE 400 dataset 
The PACE 400 study is a longitudinal follow up study. The sample consisted of all 
UHR patients who participated in research studies at the PACE clinic between 1993 
and 2006 (N = 416). For more detailed information on the cohort and the measures 
see Nelson et al., 2013. 
 
2.2 Setting  
Both studies took place at the PACE clinic in Melbourne. The PACE clinic is a 
specialist clinic for patients meeting UHR criteria aged between 15 and 25 living in 
northwestern Melbourne. For full operationalised criteria see (Yung et al., 2003).  
 
2.3 Participants & Samples 
2.3.1 Case control study 
Details of the case control participants and sample are illustrated in figure 1. 
Transition to psychosis (threshold psychotic disorder) in the clinic is determined using 
the CAARMS criteria in accordance with earlier studies (Yung et al., 2003; Yung et 
al., 2004). This operationalised definition of transition to first episode psychosis 
consists of daily frank positive psychotic symptoms for longer than one week (Yung 
et al., 2005). Cases and controls were not individually matched but they were from the 
same period of recruitment. Year of recruitment is known to be a strong predictor of 
development of a psychotic disorder (Nelson et al., 2013). There was 1 control per 
case. The time to follow-up ranged from 1.2 to 6.5 years with a median of 4.5 years. 
 
2.3.2 PACE 400 
The sample consisted of all UHR patients who participated in studies at the PACE 
clinic between 1993 and 2006 (N = 416). 396 patients from the PACE 400 sample 
were included in the analyses.  
 2.4 Symptom measures & procedure 
2.4.1 Case control study 
2.4.1.2 Symptom measures 
An auditing tool was developed specifically to gather detailed information from the 
clinical file about cases and controls, from their time of referral to four weeks 
following initial contact with a PACE clinician (Appendix 1). The auditing tool 
gathered information on hallucinations, delusions, thought disorder, negative 
symptoms, dissociative symptoms, mood symptoms, anxiety symptoms and 
personality traits. For the assessment of psychotic symptoms we included all 
symptoms assessed in the Operational Criteria for Psychotic Illness (OPCRIT) tool 
(McGuffin et al., 1991). The OPCRIT is a 90-item computer based diagnostic tool 
which generates diagnoses according to 12 operational diagnostic systems. OPCRIT 
is widely used in order to make valid diagnoses of psychotic disorders using 
information obtained from clinical files and has good validity (McGuffin et al., 1991). 
We also included additional symptom items, especially those related to symptom 
content that are not adequately covered by the OPCRIT tool, such as specific 
hallucinatory symptom content. This provided a detailed assessment of attenuated 
psychotic and other psychotic like symptoms.  
 
2.4.1.2 Assessment of psychosis diagnosis 
The OPCRIT tool was used to assess diagnosis at transition to psychotic disorder. All 
relevant data in the file up to four weeks from the date of transition was included in 
order to produce an OPCRIT diagnosis.  
 
2.4.1.3 Procedure 
The auditing tool was completed for cases and controls by a research assistant using 
information from the patients’ clinical file. To ensure completeness in the assessment 
of baseline symptomatology, we used data from the clinical notes from date of first 
contact with a PACE clinician until four weeks after first contact. All patients 
accepted into the PACE clinic received a thorough initial assessment which included 
the CAARMS and a full assessment of clinical symptoms. In the majority of cases 
relevant clinical symptoms were elicited in the initial assessment, however, in a small 
number of cases additional baseline symptomatology was elicited after this 
assessment but within the first four weeks of contact with a PACE clinician.  
 
For 'cases' that developed a psychotic disorder, the OPCRIT was also administered by 
auditing clinical notes dated from time of transition until four weeks afterwards. Only 
the DSM-IV diagnoses generated by the OPCRIT program were used. Consequently, 
the research assistant was not blind to the transition status of the individual. However, 
the research assistant was blind to the study hypothesis. The accuracy of the ratings of 
the presence/absence of the symptoms by the research assistant was regularly checked 
by one of the investigators (BN) following initial training by two investigators (AT 
and BN).  
 
2.4.2 PACE 400   
2.4.2.1 UHR status and symptom measures 
The CAARMS is a semi-structured interview that measures positive, negative, 
disorganised and other common symptoms. It allows intensity, frequency and 
duration of symptoms to be measured using one instrument (Yung et al., 2005). The 
CAARMS data included information on the presence and intensity of perceptual 
abnormalities but did not include details of hallucinatory form i.e. whether 
hallucination is visual/ auditory or other. Psychosocial functioning was measured 
using the Global Assessment of Psychosocial Functioning (GAF) (APA, 1994).  
 
2.5 Data analysis 
The outcome of interest and the dependent variable was transition to a psychotic 
disorder.  
 
In the case control study the independent variables were all symptom questions 
included in the audit tool. However, when there were small numbers of responses for 
items, it was necessary to combine or group symptoms. The number of responses to 
an item that was considered satisfactory for analysis was set at n=10 a priori. These 
groups were formed on the basis of conventional psychopathological descriptions 
(Sims, 1988), by consensus between three of the authors (BN, AT, AY) (see table 4). 
One group of 'other' hallucinatory symptoms comprising of olfactory, gustatory, 
somatic and tactile hallucinations was also formed.  
 
In PACE 400 the independent variables were the symptom scales of the CAARMS 
and GAF score. The CAARMS includes subscales on perceptual disturbance, 
disorders of thought content, conceptual disorganisation, motor disturbance, and basic 
symptom subscales. The CAARMS subscales are listed in table 5. 
 
Differences in socio-demographic characteristics in the case control study were 
examined with t-tests (age) and the chi-squared test (gender, intake group). In both 
studies, we performed a survival analysis using Log-rank test and Cox regression to 
investigate the relationship between symptom variables and transition to a psychotic 
disorder with time to transition as a time-to-event variable. In the case of binary 
factors, an exact log-rank test (based on the distribution of the sum of independent 
hypergeometric random variables) was used.  
 
A hazard ratio of less than 1 was taken to indicate a reduced risk of transition to 
psychosis for the group defined by the independent variable when compared with the 
rest of the sample without this independent variable / combination of independent 
variables.  
 
As there were a relatively large number of variables in both studies, any association of 
≤ 0.1 in the univariate analysis was then subject to a multivariate analysis, controlling 
for other possible predictive symptom variables. We then repeated this multivariate 
analysis additionally adjusting for duration of symptoms, GAF score and intake 
group. These additional adjustments were made as duration of symptoms and intake 
group, are known to be associated with transition to a psychotic disorder in our 
population (Yung et al., 2004). In the PACE 400 sample, we also controlled for 
baseline year of entry into PACE clinic, which has previously been found to be 
strongly associated with risk of transition to psychosis (Nelson et al., 2013).  
We considered using a Bonferroni correction to control for multiple analyses 
however; as we were assessing evidence about specific hypotheses this was 
considered inappropriate (Perneger, 1998).  
 
3. Results:  
 
3.1 Sample demographics 
3.1.1 Case control study 
The demographics of the sample are shown in Table 1. Males were significantly older 
than females (19.4 v 17.6 years, t=3.58, p=0.001). OPCRIT diagnoses for the case 
control study are reported in Thompson et al., 2013.  
 
    [Insert table 1 around here] 
 
3.1.2 PACE 400 
The average age at baseline in the cohort was 18.9 years old  (SD 3.4 years) and 48% 
(n= 200) of the sample were male. Demographics of the full PACE 400 dataset are 
reported in Nelson et al., 2013.  
 
3.2 Hallucinations and relationship to development of psychosis 
3.2.1 Case control study 
3.2.1.1 Univariate analysis  
Hallucinations alone at baseline were not associated with a reduced risk of transition 
to psychosis in the case control study (hazard ratio 0.83, p=0.67). Any hallucination 
and no dissociation (hazard ratio 0.54, p=0.03), visual hallucinations with no ego 
boundary disorder (hazard ratio 0.61, p=0.044), visual hallucinations with no 
substance use (hazard ratio 0.48, p=0.045) were associated with significant hazard 
ratios < 1 indicating a reduced risk of transition to psychosis. Two other symptoms 
combinations were associated with hazard ratios with p values <0.1 and were included 
in the subsequent multivariate analyses.  
The other hallucinations group was small (n = 12). We repeated the same analyses in 
this group however the numbers in each of the subgroups was n<10 and so we have 
not reported these findings due to concerns about their reliability.  
   
    [Insert table 2 around here] 
 
3.2.1.2 Multivariate analysis 
The presence of hallucinations when found in the absence of any thought disorder 
(hazard ratio 0.58, p=0.045) and visual hallucinations in the absence of substance 
misuse  (hazard ratio 0.45, p=0.045) was associated with a reduced risk of transition 
to psychosis (see table 3).  
 
     [Insert table 3 about here] 
 
3.2.2 PACE 400 
3.2.2.1 Univariate analysis 
 
Hallucinations alone at baseline were not associated with a reduced risk of transition 
to psychosis in the longitudinal follow-up data set (hazard ratio 1.09, p=0.23). 
Perceptual disturbance in the absence of conceptual disturbance (hazard ratio 0.32, 
p=0.007) was associated with a hazard ratio of less than one indicating a reduced risk 
of transition to psychosis. While perceptual disturbance in the absence of a disorder of 
concentration, attention and memory (hazard ratio 1.98, p=0.02) was associated with a 
hazard ratio of greater than 1 indicating an increased risk of transition to psychosis. 
Three other symptom combinations had p values <0.10 and were included in the 
subsequent multivariate analyses (See table 4). 
No significant relationship was found between intensity of perceptual disturbance as 
rated on the CAARMS and risk of transition or non-transition to psychosis (r= 0.23, 
p=0.54). See Table 4 for the results of the univariate analysis. 
 
          [Insert table 4 about here] 
 
 
 
3.2.2.2 Multivariate analysis 
Perceptual disturbance found in the absence of a disorder of affect or emotion  
(hazard ratio 1.68, p=0.04) and perceptual disturbance found in the absence of a 
disorder of concentration, attention or memory (hazard ratio 1.88, p=0.046) were 
found to be associated with an increased risk of transition to psychosis. (See table 5).
    
    [Insert table 5 about here] 
 
 
4. Discussion  
 
 
4.1 Principal findings 
UHR patients who present with hallucinations alone were not found to be at 
significantly lower risk of transition to psychosis in the case control study or in the 
PACE 400 sample.  
 
The case control analyses suggest that hallucinations in the absence of thought 
disorder reduce the risk of transition to psychosis by around 40% as evidenced by a 
significant adjusted hazard ratio of 0.58 in the case control when compared with the 
rest of the UHR sample without this symptom combination. The univariate analysis in 
the PACE 400 dataset replicated these findings. However, this finding was no longer 
significant once other possible confounders in the PACE 400 sample were controlled 
for. Baseline year had a very significant effect on the hazard ratio for this symptom 
combination, resulting in a small increase in the hazard ratio itself, even though the p 
value fell below the level of statistical significance.  
 
In the PACE 400 cohort, perceptual abnormalities occurring in the absence of a 
disorder of emotion or affect were found to be associated with a significantly 
increased risk of transition to psychosis. The disorder of emotion and affect subscale 
of the CAARMs rates both subjective emotional disturbance (including anhedonia 
and emotional blunting) and objective affective change (including blunting of affect, 
reduced prosody and inappropriate affect) at clinical interview. The finding that those 
people who report perceptual disturbances but have no evidence of a disorder of 
emotion or affect at clinical interview as rated on the CAARMs were at higher risk of 
transition to psychosis was initially surprising as it appeared to conflict with previous 
research which reported that co-morbid depressive symptoms increased the risk of 
transition to psychosis (Yung et al., 2003). Furthermore, depression and anxiety 
symptoms are very common over the lifetime of a psychotic illness (Buckley et al., 
2009). However, more recently a large multi-centre study and a meta analysis have 
found that co-morbid depressive and anxiety symptoms are not associated with an 
increased risk of transition to psychosis in the UHR population (Salokangas et al., 
2012; Fusar-Poli et al., 2014;). It could be that many of those young people with 
perceptual disturbance in the context of disorders of emotion and affect might be 
those with depressive disorders or emotionally unstable personality traits and some 
perceptual disturbance seen as secondary and a sequelae of these disorders whereas 
those with perceptual disturbance without disorders of emotion and affect may be 
more likely to develop a primary enduring psychotic disorder. This needs further 
study. 
  
Perceptual abnormalities in the absence of impaired attention or subjective and 
objective cognitive changes were also found to be associated with a higher risk of 
transition to psychosis as evidenced by a significant adjusted hazard ratio of greater 
than 1 in the PACE 400 cohort. The cognition and attention subscale on the CAARMs 
includes assessment of subjective changes in concentration, attention, comprehension 
and memory and objective cognitive changes, which include inattentiveness during 
interview or during brief mental status testing, e.g. serial sevens. Previous research 
has not found an association between attention and increased risk of transition to 
psychosis (Francey et al., 2005). However, some cognitive deficits including impaired 
verbal fluency, verbal and visual memory, and working memory have consistently 
been associated with increased risk of transition to psychosis in the UHR population 
(Fusar-Poli et al., 2012). As such, the finding that perceptual disturbances found in the 
absence of disorders of cognition was associated with an increased risk of transition to 
psychosis was surprising. However, it likely that this brief and broad measure of 
cognition as included in this CAARMs subscale is not sufficiently sensitive to 
identify the particular cognitive deficits associated with transition. Rating on this sub 
scale which included memory, concentration and attention may also be affected by 
mood states.   
 
Data from the case control study suggests that individual forms of hallucinations (e.g. 
auditory and visual) in isolation may not be associated with increased or reduced risk 
of transition to psychosis. However, visual hallucinations in the absence of substance 
use were associated with a 55% reduced likelihood of transition to psychosis as 
evidenced by a significant adjusted hazard ratio of 0.45 in the case control study. The 
finding that the use of psychotropic substances such as cannabis are associated with 
an increased risk of developing a psychotic illness is well documented (van Os, 2002; 
Arsenault et al., 2004; Barnett et al., 2007). Although in the PACE clinic where this 
study was conducted a relationship between substance use and transition to psychosis 
has consistently not been found (Philips et al., 2002; Thompson et al., 2013b). The 
finding that UHR young people with visual hallucinations but who do not use illicit 
substances are less likely to transition to psychosis may point to an epigenetic 
influence of substance use on the risk of developing psychosis (Rutten et al., 2009)? It 
could also be that these young people do not have the neurobiological substrate that 
might be common to patients with psychosis and substance misuse. Substance use or 
absence of substance use did not significantly alter the hazard ratios of other forms of 
hallucinations. For 20% of the young people presenting with visual hallucinations, 
these were there only attenuated psychotic symptom.  
 
4.2 Comparison with previous work 
Only one study has reported that hallucinations were predictive of transition to 
psychosis (Mason et al., 2004). This cohort study had a smaller sample size (N = 74) 
than our case control study (N = 118), with a shorter follow-up period (mean of 26 
months, SD +/- 9.2 compared to our mean of 48 months, SD +/- 21). Moreover, 
Mason and colleagues did not investigate specific forms of hallucinations or symptom 
combinations or whether risk of transition was decreased in those people who 
presented with hallucinations alone at baseline.  
 
4.3 Strengths and limitations of the study 
Case control study: 
The main strength of the case control study is that it uses data from a comparatively 
large number of UHR individuals with baseline symptom data who subsequently 
developed a psychotic disorder (N = 59). Therefore, it has the benefit of increased 
power compared to other studies in the field where numbers of transitions are 
relatively low. It is possible but unlikely that some of our controls transitioned to 
psychosis after follow-up with our median time to follow up for the controls of 4.5 
years with the range being 1.2 years to 6.5 years. However, Nelson et al. (2013) 
showed that transition to psychosis is highest in the first 2 years but continues up to 
five years after identification as UHR.  
Using clinical files to extract the symptom data is associated with some limitations. 
While all initial assessments included a standardised in-depth clinical interview and 
the completion of the CAARMS, clinicians do not complete a standardised 
assessment form. As such, we cannot be certain that data were not subject to bias due 
to some answers not being recorded systematically in the clinical files.  
Not all symptoms were present in sufficient cases to allow investigation individually 
and therefore we needed to combine a number of symptoms into broader groups. We 
set a priori the prevalence of a symptom N=10.  
 
PACE 400 
The main strength of this study is that it is the first long-term follow up of a UHR 
cohort. The sample size and duration of follow up is large when compared with 
similar studies in this field. However, no detailed information on specific types or 
form of perceptual abnormalities was available in this data. The grouping called 
perceptual abnormalities included a wide spectrum of disturbance from illusions to 
frank hallucinations.  
 
4.4 Clinical Implications 
The data indicate that in the UHR population hallucinations on their own (i.e., in the 
absence of any other attenuated psychotic symptoms) are of clinical significance and 
should not be dismissed as incidental or insignificant. However, there may be certain 
combinations such as hallucinations in the absence of thought disorder, which may 
make transition to psychosis less likely and others such as hallucinations in the 
absence of disorders of emotion, and affect which make transition to psychosis more 
likely.  
Returning to the analogy of temperature and fever. Like a fever, perceptual 
disturbance appears to be a non-specific clinical feature, which may represent the end 
point of a number of clinical pathways. It may be that like a fever the true clinical 
significance of a hallucination is defined less by to its own clinical features and better 
understood by the presence or absence of other signs and symptoms. 
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Table1  
 
Case control study: Demographics of total sample, cases and controls at 
baseline 
 
 Total 
sample 
n= 118 
Cases 
n= 59 
Controls 
n=59 
P value ^ 
Age, mean (SD) 18.3 (2.7) 18.6 (2.6) 18 (2.9) 0.54 + 
Gender, female (%) 69 (58.5) 34 (57.6) 35 (59.3) 0.71 
Highest Education, 
number (%) # 
Secondary yr 7‐10  
Secondary yr 11‐12  
Tertiary commenced 
 
 
48 (41.4)  
50 (43.1) 
16 (13.8)  
 
 
24 (41.4) 
25 (43.1) 
9   (15.5) 
 
 
24 (42.9) 
25 (44.6) 
7   (12.5) 
 
 
0.52 
0.53 
0.23 
Occupation,  
number (%)  
Full time/part time 
 
 
16 (13.6) 
 
 
5 (8.5) 
 
 
7 (11. 9) 
 
 
0.25 
work 
Full time/part time 
student 
Unemployed 
 
57 (48.3) 
 
50 (42.4) 
 
28 (47.5) 
 
26 (44.1) 
 
29 (49.2) 
 
21 (35.6) 
 
0.20 
 
0.08 
Duration of psychotic 
symptoms, 
mean in weeks (SD) ^ 
 
 
35 (44.4) 
 
 
34.1 (48.2) 
 
 
36.1 (41.2) 
 
 
0.86 
Duration of mood 
symptoms, mean in 
weeks (SD) ~ 
 
  
31 (40.5) 
 
 
31.2 (43.5) 
 
 
31.4 (38.1) 
 
 
0.65 
Living status, number 
(%)   
Not with parents 
With parents 
 
 
39 (33.1) 
79 (67.0) 
 
 
17 (28.8) 
42 (71.2) 
 
 
22 (37.3) 
37 (62.7) 
 
 
0.06 
0.06 
Hx of substance use, 
number (%) > 
 
66 (56.9) 
 
35 (59.3) 
 
31 (54.4) 
 
0.30 
UHR Intake group, 
number (%) 
Trait 
APS 
BLIPS 
APS& BLIPS 
APS & Trait 
APS & Trait & BLIPS 
 
 
32 (27.1) 
104 (88.1) 
4 (3.4) 
1 (0.8) 
20 (16.9) 
1(0.8) 
 
 
19 (32.2) 
53 (89.8) 
3 (5.1) 
1 (1.7) 
15 (25.4) 
- 
 
 
13 (22.0) 
52 (88.1) 
1 (1.7) 
- 
5  (4.2) 
1 (1.7) 
 
 
0.01*  
0.56  
0.04*  
-  
0.001*  
-  
N= 118 unless otherwise stated #N=114 ^n=113 ~n=112  > n=116 
+ p value associated with t test 
^ p value associated with chi-squared test 
*statistical significance set at p<0.05 
 
 
 
 
 
 
 
Table 2 
 
Case control study: Prevalence of hallucinations with associated hazards ratios 
(and p value) of developing a psychotic disorder 
 
Symptom items Number with 
item present 
(%) 
Hazards Ratio 
(95% CI) 
P value * 
Any Hallucination  (n=80)    
Any hallucination only   14  (11.9) 0.83 (0.36, 1.94) 0.67 
Any hallucination with:  
                     + any delusion 56  (47.5) 1.54 (0.73, 3.26) 0.26 
     No delusion 24  (20.3) 0.58 (0.29, 1.20) 0.14 
                     + any thought 
                      Disorder ^ 
19  (16.1) 1.14 (0.58, 2.25) 0.72 
                     No thought disorder 61  (51.7) 0.65 (0.39, 1.08) 0.09* 
                     + ego boundary 
                      Disorder ^^ 
63  (53.3) 1.62 (0.84, 3.12) 0.15 
                     No ego boundary 
                      Disorder 
17  (14.4) 0.66 (0.39, 1.12) 0.12 
                     + negative symptoms 33  (28) 0.64 (0.35, 1.19) 0.16 
                     ^^^ 
                     No negative symptoms 48  (40.7) 0.97 (0.58, 1.64) 0.92 
                     + dissociation 10  (8.5) 0.96 (0.39, 2.41) 0.93 
                     No dissociation 70  (59.3) 0.54 (0.31, 0.94) 0.03* 
                     + substance use 48  (40.7) 1.18 (0.70, 1.98) 0.53 
                     No substance use 32  (27.2) 0.56 (0.30, 1.06) 0.07* 
    
Auditory Hallucinations (n=60)    
Auditory hallucination only 12  (10.2) 0.84 (0.51, 1.40)  0.52 
   Auditory hallucination with:  
                     + any delusion 40  (33.9) 1.49 (0.64, 3.48) 0.35 
     No delusion 20  (16.9)   
                     + any thought 
                        Disorder 
10  (8.5) 1.49 (0.64, 3.48) 0.35 
                     No thought disorder 50  (42.4) 0.73 (0.44, 1.24) 0.25 
                     + ego boundary 
                        Disorder 
14  (11.9) 1.51 (0.74, 3.01) 0.26 
                     No ego boundary 
                        Disorder 
46  (39.0) 0.69 (0.42, 1.13) 0.14 
                      + negative symptoms 23  (19.5) 2.10 (0.72, 6.09) 0.16 
                      No negative symptoms 37  (31.4) 0.87 (0.5, 1.52) 0.63 
                      + dissociation 4    (3.4) 0.94 (0.23, 3.85) 0.93 
                      No dissociation 56  (47.5) 0.85 (0.51, 1.41) 0.52 
                      + substance use 36  (30.5) 1.19 (0.70, 2.04) 0.52 
                      No substance use 24  (20.3) 0.66 (0.33, 1.35) 0.26 
    
Visual Hallucinations (n=55)    
Visual hallucination only 7  (5.9) 1.22 (0.44, 3.37) 0.70 
Visual hallucination with: 
                      + any delusion 31( 26.3) 0.68 (0.41, 1.15) 0.14 
                      No delusion 14 (11.9) 0.56 (0.23, 1.41) 0.22 
                      + any thought 
                         Disorder 
16 (13.6) 1.08 (0.51, 2.28) 0.84 
                      No thought disorder 39 (33.1) 0.62 (0.34, 1.10) 0.10 
                      + ego boundary 
                      Disorder 
13 (11.0) 1.40 (0.66, 2.95) 0.38 
                      No ego boundary 
                      Disorder 
42 (35.6) 0.61 (0.35, 0.95) 0.044* 
                      + negative symptoms 21(17.8) 0.55 (0.25, 1.20) 0.13 
                      No negative symptoms 34 (28.8) 0.93 (0.53, 1.70) 0.80 
                         + dissociation 8   (6.8) 1.04 (0.38, 2.90) 0.95 
                      No dissociation 47 (39.8) 0.67 (0.39, 1.14) 0.14 
                      + substance use 30 (25.4) 1.08 (0.61, 1.93) 0.78 
                      No substance use 25 (21.2) 0.48 (0.29, 1.01) 0.045* 
*statistical significance set at p<0.05 however p<0.1 was subject to subsequent multivariate analysis 
^Thought disorder group included neologisms, thought blocking, loosening of associations or derailment and 
tangentiality, flight of ideas and racing thoughts, circumstantiality, perserveration or echolalia and poverty of 
speech. 
^^Delusion of ego boundary group included passivity, thought insertion, thought withdrawal, thought broadcast, 
thoughts being read, made thoughts or feelings.  
^^^Negative symptoms group included alogia, avolition, apathy, anhedonia, affective flattening. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:   
Case control study 
Adjusted analysis of the joint significance of variables that were associated with 
a p value of predictors ≤ 0.1 in the univariate analysis (Table 2) 
 
Symptom items Hazards Ratio (95% 
CI) 
P value * 
Any hallucination with 
 
  
No thought disorder 0.58 (0.33, 0.98) 0.045* 
No dissociation 0.58 (0.33, 1.02) 0.06 
No substance use 0.55 (0.28, 1.06) 0.08 
Visual hallucination with 
 
  
No ego boundary disorder 0.59 (0.32, 1.07) 0.08 
No substance use 0.44 (0.20, 0.98) 0.045* 
*statistical significance set at p<0.05 however p<0.1 was subject to subsequent multivariate analysis 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
PACE 400 
Frequency of perceptual abnormalities and frequency of perceptual abnormalities in 
combination with other CAARMS scales and the associated hazards ratios (and p 
value) of developing a psychotic disorder.  
 
CAARMS scales Number with 
item present 
(%) 
 
N= 396 
Hazards 
Ratio (95% 
CI) 
P value * 
Any Perceptual abnormality  300 (75.6) 1.09  
(0.95, 1.27) 
0.23 
Perceptual abnormality only 119 (29.6) 1.31  
(0.87, 1.96) 
0.20 
Perceptual abnormality with: 
+ disorder of thought content 277 (68.9) 1.05  
(0.67, 1.65) 
0.83 
 No disorder of thought content 23 (6.1) 0.60  0.31 
(0.22, 1.62) 
 +  conceptual disorganization 238 (59.2) 1.44  
(0.94, 2.23) 
0.11 
 No conceptual disorganization 61 (15.2) 0.32  
(0.14, 0.73) 
0.007* 
+ motor disturbance 89 (22.1) 1.39  
(0.90, 2.15) 
0.14 
No motor disturbance 209 (52.0) 0.69  
(0.46, 1.03) 
0.07* 
+ disorders of emotion and affect 222 (55.2) 0.72  
(0.49, 1.07) 
0.11 
No disorders of emotion and affect 76 (18.9) 1.41  
(0.89, 2.24) 
0.10* 
+ impaired energy 248 (61.7) 0.75  
(0.50, 1.12) 
0.16 
No impaired energy 50 (12.4) 1.42  
(0.84, 2.39) 
0.20 
+ impaired tolerance to normal stress 299 (74.4) 0.92  
(0.58, 1.49) 
0.75 
No impaired tolerance to normal stress 53 (13.2) 1.32  
(0.78, 2.23) 
0.30 
+ disorder of concentration, attention and 
memory 
268 (67.7) 0.69  
(0.47, 1.02) 
0.06* 
No disorder of concentration, attention and 
memory 
31 (7.7) 1.98  
(1.10, 3.55) 
0.02* 
+ basic symptom: impaired emotional 
functioning 
28 (7.0) 0.56  
(0.23, 1.36) 
0.20 
+ basic symptom: impaired energy 16 (4.0) 0.69  
(0.22, 2.17) 
0.52 
+ basic symptom: impaired motor functioning 13 (3.2) 0.92  
(0.30, 2.99) 
0.95 
+ basic symptom: impaired bodily sensation 12 (3.0) 0.71  
(0.17, 2.87) 
0.71 
+ basic symptom: impaired external perception 24 (6.0) 0.84  
(0.37, 1.92) 
0.68 
+ basic symptom: impaired autonomic 
functioning 
10 (2.5) 0.35  
(0.05, 2.47) 
0.29 
* Statistical significance = p<0.05 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 
PACE 400 
 
Adjusted analysis of the joint significance of variables that were associated with a p 
value of predictors ≤ 0.1 in the univariate analysis 
 
 
CAARMS scales 
 
Hazards Ratio 
(95% CI) 
P 
value 
* 
Perceptual abnormality with no 
conceptual disorganization 
0.49 (0.17, 1.37) 0.18 
Perceptual abnormality with disorder 
of concentration, attention and 
memory 
0.84 (0.54, 1.31) 0.45 
Perceptual abnormality with no motor 
disturbance 
1.25 (0.80, 1.96) 0.33 
Perceptual abnormality with no 
disorder of emotion and affect 
1.68 (1.02, 2.76)  0.04* 
Perceptual abnormality with no 
disorder of concentration, attention 
and memory 
1.88 (1.01, 3.52) 0.046* 
* Statistical significance = p<0.05 
 
 
Figure 1 Case Control Methodology 
 
 
Highlights 
 
 The aim of this study was to investigate whether UHR patients who present with 
hallucinations alone at identification as UHR are at lower risk of transition to 
psychosis than UHR patients who present with no hallucinations or hallucinations 
plus other symptoms. 
 Our primary dataset was a retrospective “case-control” study of UHR patients (N 
= 118). The second, independent dataset was a long-term longitudinal follow up 
study of UHR patients (N = 416).  
 Hallucinations alone at baseline were not significantly associated with a reduced 
risk of transition to psychosis.  
 In the longitudinal follow-up dataset perceptual disturbance found in the absence 
of a disorder of affect or emotion was associated with an increased risk of 
transition to psychosis. 
 
Figure 1 
Case Control Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cases                      Controls 
 
A consecutive series of patients    
who later developed a psychotic  
disorder (‘cases’) between 2003  
and 2008. 
 
 
 
 
 
 
 
 
       
     
 
 
 
 
 
 
 
 
 
 
               
 
 
 
 
 
 
 
Subjects who were known to have not 
transitioned on 31/01/2010 
   
'Non transition' status established 
by: 
 Contact with the PACE clinic 
 Central PACE database 
which included follow-up 
research assessments   
 Victorian public mental 
health client information 
management system 
 
           N=539 
 
Random number 
generation 
   59 Controls 
Transition Status: 
Transition to psychosis was 
operationally defined as at least 1 
fully positive psychotic symptom 
several times a week for more 
than 1 week.  
 
        N=65 
 
 
 
 
    59 Cases 
 
The PACE clinic is a specialist clinic for patients meeting UHR 
criteria aged between 15 and 25 living in northwestern 
Melbourne. 
All individuals accepted into the PACE clinic between 30/6/2003 
and 31/10/2008 inclusively were included in the sample; there 
were no exclusions (N=605) 
 
The time to follow-up ranged from 1.2 to 6.5 years with a median 
of 4.5 years. 
6 cases had 
transitioned at time 
of entry to clinic 
6. Figure(s)
